Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
1.2 nM 396.5 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 M4LZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny5NE42KM7:TR?= NHjjd2o4OiCq MoHWSG1UVw>? NILUdYRKSzVyPUCuNFQh|ryP NVvDVHdbOjZzM{[2PFQ>
LS174T M33lZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmwMlUh|ryP M{LCe|czKGh? Mlv4SG1UVw>? MVrJR|UxRTBwMEWg{txO NVvreHpbOjZzM{[2PFQ>
T84 NXr6UHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTOZlZxOC53IN88US=> NH;lemc4OiCq MXPEUXNQ NYW0N3A4UUN3ME2wMlA6KM7:TR?= NELwXokzPjF|Nk[4OC=>
LS180 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXCNE42KM7:TR?= NH[0VGg4OiCq MkXqSG1UVw>? MWLJR|UxRTFizszN M3rEVVI3OTN4Nki0
SW948 NFLFT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT3[Gd3OC53IN88US=> NGf1W2M4OiCq NIHLXHNFVVOR Mn7uTWM2OD1zIN88US=> NGLH[mczPjF|Nk[4OC=>
HCT15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hz[|AvPSEQvF2= NWPVeGo3PzJiaB?= MYfEUXNQ Ml;DTWM2ODxyLkSg{txO MojRNlYyOzZ4OES=
DLD-1 NXGxUW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2XYQ2OC53IN88US=> NGTXOFg4OiCq NV\KRmxyTE2VTx?= NUHuPGx3UUN3MEywMlgh|ryP MXiyOlE{PjZ6NB?=
MIP-101 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTkNE42KM7:TR?= MmfNO|IhcA>? M120VWROW09? MVLJR|UxRTFizszN MXeyOlE{PjZ6NB?=
SNU1544 M2nsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TBWlAvPSEQvF2= MUG3NkBp NFi4V2tFVVOR MXTJR|UxRTFizszN NXnISld{OjZzM{[2PFQ>
OCI-Ly10 MUHDfZRwfG:6aXOgRZN{[Xl? M{TYR|czKGh? M{TiNWROW09? NHK4[ZhKSzVyPUCuNFU5KM7:TR?= M{HXTFI2QDd6M{Ox
SU-DHL2 Ml3oR5l1d3SxeHnjJGF{e2G7 MmjMO|IhcA>? M3\TSWROW09? M17WR2lEPTB;MD6wNUDPxE1? M{W0fFI2QDd6M{Ox
OCI-LY7 NIHoXHpEgXSxdH;4bYMhSXO|YYm= M4\BblczKGh? MmLhSG1UVw>? MYPJR|UxRTBwMEixJO69VQ>? NI\XWY0zPTh5OEOzNS=>
SU-DHL6 MU\DfZRwfG:6aXOgRZN{[Xl? M{\D[|czKGh? MU\EUXNQ NGDyc|hKSzVyPUCuOFgzKM7:TR?= MmPhNlU5Pzh|M{G=
Jeko-1 MVnDfZRwfG:6aXOgRZN{[Xl? M4jTclczKGh? MVTEUXNQ M2G1OWlEPTB;MD6wNlkh|ryP NVHqbHkyOjV6N{izN|E>
JVM-2 NXe2enpoS3m2b4TvfIlkKEG|c3H5 NWDxUldZPzJiaB?= NGC5So1FVVOR M{PkVWlEPTB;MD6wNUDPxE1? M{LYTFI2QDd6M{Ox
Rec-1 NVvUSHhbS3m2b4TvfIlkKEG|c3H5 NYnVfpBXPzJiaB?= M{e1SmROW09? NV3RNZdVUUN3ME2wMlA5PyEQvF2= MkPkNlU5Pzh|M{G=
Z-138 MnuyR5l1d3SxeHnjJGF{e2G7 NWO1bFdUPzJiaB?= MXzEUXNQ NYnISFZ2UUN3ME2wMlAyOyEQvF2= MnS2NlU5Pzh|M{G=
H9 MY\DfZRwfG:6aXOgRZN{[Xl? MlHYO|IhcA>? MYXEUXNQ NV65N2NuUUN3ME2wMlYh|ryP M3rYWlI2QDd6M{Ox
HH M4LTZmN6fG:2b4jpZ{BCe3OjeR?= M{\DUVczKGh? Mm\TSG1UVw>? MnXyTWM2OD1yLkeg{txO MY[yOVg4QDN|MR?=
DND41 MULDfZRwfG:6aXOgRZN{[Xl? MWO3NkBp M33GZ2ROW09? MlrTTWM2OD1yLkGg{txO MUmyOVg4QDN|MR?=
CCL119 NFrYOo5EgXSxdH;4bYMhSXO|YYm= MmXUO|IhcA>? NYfwWnFLTE2VTx?= NEXMT5VKSzVyPUCuNFYzKM7:TR?= MkToNlU5Pzh|M{G=
J.Cam 1.6 NFHIW4REgXSxdH;4bYMhSXO|YYm= M1;HVlczKGh? NGT6TlhFVVOR NV3ESFUxUUN3ME2wMlExPSEQvF2= MWiyOVg4QDN|MR?=
Sup-T1 MkDLR5l1d3SxeHnjJGF{e2G7 MYO3NkBp NWDTVW1wTE2VTx?= M1LBN2lEPTB;Mj6xOFIh|ryP MoDINlU5Pzh|M{G=
Tib 152 MUDDfZRwfG:6aXOgRZN{[Xl? M2TRc|czKGh? NIPBPHJFVVOR MkLXTWM2OD1yLkig{txO NWO5O5U5OjV6N{izN|E>
MCF7 MWrGeY5kfGmxbjDBd5NigQ>? M2D2XlUh|ryP MUmyOEBp Mlf1SG1UVw>? NXTmeIdWUW6mdXPld{BIOi:PIHHydoV{fA>? NXHNWW9iOjV6M{S0NFE>
MDA-MB-231 NVKx[Ih2TnWwY4Tpc44hSXO|YYm= MlfqOUDPxE1? MXGyOEBp M{LIPWROW09? Mn;zTY5lfWOnczDHN{9OKGG{cnXzeC=> NYq5eoYyOjV6M{S0NFE>
MCF7 Mm\BSpVv[3Srb36gRZN{[Xl? M4qzd|Uh|ryP NILIfFIzPCCq MUHEUXNQ M4PX[GRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= MmLsNlU5OzR2MEG=
MCF7 MkTJSpVv[3Srb36gRZN{[Xl? MlTXOUDPxE1? NUT0WnBlOjRiaB?= NYWxU|FMTE2VTx?= Ml3PSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> NH\SenIzPTh|NESwNS=>
MCF7 NX63ZoljTnWwY4Tpc44hSXO|YYm= MlWxOUDPxE1? M2jhWVI1KGh? MUDEUXNQ NEj0Vo9F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NX[1R45VOjV6M{S0NFE>
MCF7 MUfGeY5kfGmxbjDBd5NigQ>? Ml3qOUDPxE1? MWmyOEBp M3vURWROW09? NHeyVHhKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? MVGyOVg{PDRyMR?=
MCF7 MkPrSpVv[3Srb36gRZN{[Xl? NXi4SpFsPSEQvF2= MmTZNlQhcA>? Ml3KSG1UVw>? NG\FXnlKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= NUH4O|Z7OjV6M{S0NFE>
MDA-MB-231 MnrwSpVv[3Srb36gRZN{[Xl? M{S1T|Uh|ryP Mny4NlQhcA>? M{Tv[2ROW09? NITJS21F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy NIOwSlAzPTh|NESwNS=>
MDA-MB-231 NXHi[4VXTnWwY4Tpc44hSXO|YYm= NHq2cXQyKM7:TR?= Mlz1NlQhcA>? NHrIUI9FVVOR M3fpdmlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz M3nKclI2QDN2NECx
MDA-MB-231 MXnGeY5kfGmxbjDBd5NigQ>? Ml\rOUDPxE1? NGm5XlAzPCCq MlHQSG1UVw>? NHfkbJlF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NXLRVGRoOjV6M{S0NFE>
MDA-MB-231 MkDQSpVv[3Srb36gRZN{[Xl? M4\l[FUh|ryP MWCyOEBp NHjnb3RFVVOR NHnYWIhKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? MljuNlU5OzR2MEG=
MDA-MB-231 MWDGeY5kfGmxbjDBd5NigQ>? M3vSUlUh|ryP NWfaUmtXOjRiaB?= MYXEUXNQ MXzJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? M4PDeVI2QDN2NECx
MDA-MB-231 NFjUPGtHfW6ldHnvckBCe3OjeR?= MlvvOUDPxE1? M3LZOlI1KGh? NE\seWxFVVOR MWTJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEWz NXP3dotzOjV6M{S0NFE>
MCF7 M4PvTGFxd3C2b4Ppd{BCe3OjeR?= M{fydVUh|ryP Mk\VNlQhcA>? MYfEUXNQ M{DqVWlv\HWlZYOgZZBweHSxdHnjJIRm[XSq NEHpdZMzPTh|NESwNS=>
MDA-MB-231 MWnBdI9xfG:|aYOgRZN{[Xl? NYnjflNRPSEQvF2= M4Hre|I1KGh? MXTEUXNQ M4T6OGlv\HWlZYOgZZBweHSxdHnjJIRm[XSq MlHmNlU5OzR2MEG=
MCF7 MWDGeY5kfGmxbjDBd5NigQ>? NIHxNGkyKM7:TR?= NGnjWpo4OiCq M2W4N2ROW09? MVXJcoR2[2W|IHH1eI9xcGGpaXOg[IVifGh? M1vPSFI2QDN2NECx
MDA-MB-231 MYnGeY5kfGmxbjDBd5NigQ>? NWjQUoJCOSEQvF2= M2LNclczKGh? MVrEUXNQ M1PJXWlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= NVnQUGoxOjV6M{S0NFE>
U-2 OS NHzw[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLlcGw2OCEQvF2= MWOyOEBp MUTEUXNQ MXzJR|UxRTF4Lk[g{txO M1rteFI2Pzl{OEGx
MG-63 NHyxeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS1NEDPxE1? M3fmTlI1KGh? M2T5SWROW09? Mor0TWM2OD17LkWg{txO Mmj2NlU4QTJ6MUG=
U-2 OS Mn\6RZBweHSxc3nzJGF{e2G7 MV21JO69VQ>? M4G4UVI1KGh? MWrEUXNQ NFnkXHBKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NVTvNlR1OjV5OUK4NVE>
MG-63 NIXhe|hCeG:ydH;zbZMhSXO|YYm= NEPISZo2KM7:TR?= MYqyOEBp MWnEUXNQ M33Z[mlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> NHXtbHkzPTd7MkixNS=>
U-2 OS MV\GeY5kfGmxbjDBd5NigQ>? NWT3NHdvPSEQvF2= MnnJNlQhcA>? MXvEUXNQ NGC0PZpRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NEPwWGczPTd7MkixNS=>
MG-63 MmTuSpVv[3Srb36gRZN{[Xl? MmftOUDPxE1? NELH[VQzPCCq MofxSG1UVw>? MXPQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> MmLHNlU4QTJ6MUG=
PANC-1 NUfC[44zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHqOVAh|ryP M3TnOlI1KGh? MUPEUXNQ MonPTWM2OD15LkGg{txO MoT3NlU3OzJ{MkW=
BxPC-3 NWfiSZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnzO3U2OCEQvF2= NV:xSmdsOjRiaB?= NHSyV29FVVOR MWfJR|UxRTZwODFOwG0> MUKyOVY{OjJ{NR?=
PANC-1 NFLBV4hHfW6ldHnvckBCe3OjeR?= MWi1JO69VQ>? MYiyOEBp MUnEUXNQ MVPJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> MWOyOVY{OjJ{NR?=
BxPC-3 MXrGeY5kfGmxbjDBd5NigQ>? M{PmPVUh|ryP NWOxUYJPOjRiaB?= NWnCcmNsTE2VTx?= M2rH[2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? Mn7XNlU3OzJ{MkW=
PANC-1 MWLGeY5kfGmxbjDBd5NigQ>? NHT6fmc2KM7:TR?= M3iyZ|I1KGh? MY\EUXNQ NILDO3VKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NWKyXplWOjV4M{KyNlU>
BxPC-3 NFv2WnpHfW6ldHnvckBCe3OjeR?= M4rmfVUh|ryP NXz1UG5NOjRiaB?= NVrJS2lOTE2VTx?= MkDJTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MYKyOVY{OjJ{NR?=
SKOV3 NH7CfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNFAh|ryP MX2yOEBp MmTiSG1UVw>? MVXJR|UxRTJyLkS4JO69VQ>? NHO2eoQzPTZ{NEe1NC=>
OVCAR4 M4PNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr4NVAxKM7:TR?= MoDxNlQhcA>? NGLqZ4lFVVOR NGnYVIRKSzVyPUKyMlE{KM7:TR?= M3[1bFI2PjJ2N{Ww
SKOV3 MYfGeY5kfGmxbjDBd5NigQ>? MUW1JO69VQ>? M1;2SFczKGh? MoXBSG1UVw>? MW\JcoR2[2W|IFeyM20h[XK{ZYP0 M{HGfFI2PjJ2N{Ww
OVCAR4 Mly3SpVv[3Srb36gRZN{[Xl? NYL0NWl[PSEQvF2= NGrwS2U4OiCq MYHEUXNQ MnXHTY5lfWOnczDHNk9OKGG{cnXzeC=> M1jzSFI2PjJ2N{Ww
SKOV3 MkXoRZBweHSxc3nzJGF{e2G7 NHPGfJM2KM7:TR?= NELSPVkzPCCq NWTMW4VJTE2VTx?= MoTBTY5lfWOnczDhdI9xfG:|aYO= Mm\4NlU3OjR5NUC=
OVCAR4 M3vqeGFxd3C2b4Ppd{BCe3OjeR?= NX2zUIhMPSEQvF2= Mn6zNlQhcA>? M{XvWWROW09? M16xb2lv\HWlZYOgZZBweHSxc3nz NVjwb3l2OjV4MkS3OVA>
AGS NEfiS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG1NYdrOjVizszN MlLXNlQhcA>? M4j1PGROW09? MVLJR|UxRTF7LkC5JO69VQ>? MnrHNlU3ODl7MkO=
NCI-N78 NEnSdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnCdWczPSEQvF2= M{O5UlI1KGh? NULCXlVkTE2VTx?= MWXJR|UxRTJ4LkOzJO69VQ>? NIfyRnMzPTZyOUmyNy=>
AGS NF3rXFZCeG:ydH;zbZMhSXO|YYm= M2f3T|Uh|ryP M{PKTlI1KGh? Mnq5SG1UVw>? MnrrTY5lfWOnczDhdI9xfG:|aYO= MYOyOVYxQTl{Mx?=
NCI-N78 Mki1RZBweHSxc3nzJGF{e2G7 NXPUWWJrPSEQvF2= NVfidIR2OjRiaB?= M{TXXmROW09? NUPWS|NqUW6mdXPld{BieG:ydH;zbZM> NITp[HUzPTZyOUmyNy=>
AGS Ml3zSpVv[3Srb36gRZN{[Xl? Mn3KOUDPxE1? M1zYTlI1KGh? MoHUSG1UVw>? NX20fGNXUW6mdXPld{B1cGViYYX0c5Bp[We7 MlXhNlU3ODl7MkO=
NCI-N78 Ml6xSpVv[3Srb36gRZN{[Xl? NH\xfHM2KM7:TR?= NEHa[XozPCCq NIm0WnFFVVOR M3TqZWlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? MUWyOVYxQTl{Mx?=
HSC-3 NEPEZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxJO69VQ>? NVHDNXk1PDhiaB?= NFLz[YNKSzVyPUCuOVQh|ryP NVzrZm11OjV|Nk[xOFM>
GB30 M3jubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLkOlRkOSEQvF2= NEDYb2k4KGR? MXzEUXNQ MV\JR|UxRTBwMEGxJO69VQ>? NF7zTFczPTFyNkSyPC=>
GB9 M{PMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ixR|Eh|ryP MknTO{Bl MYDEUXNQ NITDcmpKSzVyPUCuNFI1KM7:TR?= MU[yOVExPjR{OB?=
GB169 M33FbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfVbmlvOSEQvF2= MXe3JIQ> NGO5[m5FVVOR NELPRVNKSzVyPUCuNFMzKM7:TR?= NXrONGR5OjVzME[0Nlg>
T24 NEjzTGNHfW6ldHnvckBCe3OjeR?= M{n1NlEh|ryP M2H6RVQ5KGh? MmS0SG1UVw>? MYTJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NVvlVo9vOjN2MEO2N|M>
RT4 MoTrSpVv[3Srb36gRZN{[Xl? M1HuN|Eh|ryP NIi2Ook1QCCq M2XS[GROW09? NXHwUJdMUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MkPiNlM1ODN4M{O=
UM-UC-3 NGDRW2NHfW6ldHnvckBCe3OjeR?= MXWxJO69VQ>? NWK1elNFPDhiaB?= NHTJbJpFVVOR MoH1TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= Ml6zNlM1ODN4M{O=
T24 MkLzRZBweHSxc3nzJGF{e2G7 NWPOeXdFOy5zNjFOwG0> NEfjO2g6PiCq MXTEUXNQ MmLvTWM2OD1yLkCzNFYh|ryP MnHNNlM1ODN4M{O=
RT4 NYriR40{SXCxcITvd4l{KEG|c3H5 NYrrd5BUOy5zNjFOwG0> M4XYcVk3KGh? NXe5O|FXTE2VTx?= M3\zfGlEPTB;MD6xNVk5KM7:TR?= Ml\tNlM1ODN4M{O=
UM-UC-3 NIXTWZRCeG:ydH;zbZMhSXO|YYm= MnH3N{4yPiEQvF2= NE\MVWw6PiCq MXjEUXNQ NWHJOlBmUUN3ME2wMlA1PDlizszN MmfmNlM1ODN4M{O=
OVCAR-5 NX\Xe5R{TnWwY4Tpc44hSXO|YYm= NUfsOI9OPTBibl2= MUXJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>? NXv4T4R[OjN|M{SzNlc>
SKOV3ip2 NFniWVVHfW6ldHnvckBCe3OjeR?= MkCzOVAhdk1? M17ZUGlvcGmkaYTzJINmdGxibXnndoF1cW:w NVr6fWNSOjN|M{SzNlc>
S462 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojHNVAxKM7:TR?= NIjLdIk4OiCq MYjEUXNQ NYr4dFhySXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= NYjmTVJMOjN|MkixNVQ>
2884 M4XoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jmV|ExOCEQvF2= M370UVczKGh? M17UVGROW09? NEmz[3FCfHSnboXheIV{KGOnbHyg[5Jwf3Sq MV2yN|MzQDFzNB?=
2885 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqxNFAh|ryP M33wdlczKGh? NGXPfW5FVVOR NEHKSFBCfHSnboXheIV{KGOnbHyg[5Jwf3Sq M3PRN|I{OzJ6MUG0
CRL-2396 M2\6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjzNVAxKM7:TR?= NXjFflRmf2G2ZYK= NHq3SJpKSzVyPUCuNFkzKM7:TR?= NGi3XXczOzF3M{WyOC=>
TIB-48 NIfEWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGxNFAh|ryP M4npepdifGW{ NFHGNVJKSzVyPUCuNFg5KM7:TR?= M{TQO|I{OTV|NUK0
CRL-2396 MnmzR5l1d3SxeHnjJGF{e2G7 MYqxJO69VQ>? NXntXlE{PDhiaB?= NUnMNoduf2G2ZYK= MlGxTY5lfWOnczDhdI9xfG:|aYO= M4XWXVI{OTV|NUK0
TIB-48 MXjDfZRwfG:6aXOgRZN{[Xl? Mlq5NUDPxE1? M3fI[VQ5KGh? NXHWPXlHf2G2ZYK= NX;5VYJCUW6mdXPld{BieG:ydH;zbZM> NH7M[IgzOzF3M{WyOC=>
AGS M3rXdmN6fG:2b4jpZ{BCe3OjeR?= NGLzPJkxNjVizszN MYGyOEBp MULEUXNQ NIHmTnFF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= Mn7XNlI6PzJ4MUG=
FLO-1 MX;DfZRwfG:6aXOgRZN{[Xl? M3e2OFAvPSEQvF2= NVjOeHVOOjRiaB?= NY\md4NsTE2VTx?= MVfE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NVrENFEzOjJ7N{K2NVE>
OE33 NHPPbJlEgXSxdH;4bYMhSXO|YYm= NEDCdGgxNjVizszN NV3PcVhTOjRiaB?= M4f0Z2ROW09? M13WSGRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu MV[yNlk4OjZzMR?=
SKLMS M1PXc2N6fG:2b4jpZ{BCe3OjeR?= MX63OUBvVQ>? M2e5Nlk3KGh? MXHJcoR2[2W|IHHwc5B1d3Orcx?= MUGyNlgzOTl7Nx?=
Leio285 M{HRUmN6fG:2b4jpZ{BCe3OjeR?= M1HGb|c2KG6P MUK5OkBp NFzLTndKdmS3Y3XzJIFxd3C2b4Ppdy=> NYP1ZohJOjJ6MkG5PVc>
Mes-Sa M3vnbWN6fG:2b4jpZ{BCe3OjeR?= M3[1Rlc2KG6P NELNPHQ6PiCq MkXSTY5lfWOnczDhdI9xfG:|aYO= NEnrXJkzOjh{MUm5Oy=>
DAOY MlXoR5l1d3SxeHnjJGF{e2G7 NUOySoVsOTBizszN M{nEUVczKGh? NWDtc5VmTE2VTx?= MmjITWM2OD1yLkC0JO69VQ>? MWSyNlY3QTN|NR?=
IMR32 NEX1bHhEgXSxdH;4bYMhSXO|YYm= NYPqWWV1OTBizszN MnLlO|IhcA>? NYrvU3Z3TE2VTx?= MlrDTWM2OD1yLkCzJO69VQ>? MYSyNlY3QTN|NR?=
Molt-4 MW\DfZRwfG:6aXOgRZN{[Xl? NYjXdodCOTBizszN MWG3NkBp MVTEUXNQ M3;hbGlEPTB;MD6wNkDPxE1? NEDLTlAzOjZ4OUOzOS=>
MOLM-13 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjoOVZTOyEQvF2= MmW0O|IhcA>? NUDXUHp4TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MYOyNlQ5QDJ2OR?=
HL-60 NYXmXmlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmzJO69VQ>? NE\sZos4OiCq M37VXmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M{fOWVIzPDh6MkS5
MV4-11 M123V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtdZI{KM7:TR?= NGX0bmo4OiCq M1izZ2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NECxUIYzOjR6OEK0PS=>
SKM-1 NVrSSI1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LPVlMh|ryP NHLPOlk4OiCq MUDEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MmDhNlI1QDh{NEm=
SH2 NIjvboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqzJO69VQ>? MXq3NkBp MYfEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MUKyNlQ5QDJ2OR?=
NOMO-1 NX;KSVRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqzJO69VQ>? NITvOXg4OiCq MlXoSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MUKyNlQ5QDJ2OR?=
OCL-AML2 NUnhU2FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfIeJg{KM7:TR?= NYXEZndHPzJiaB?= NUPYOFlrTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MVmyNlQ5QDJ2OR?=
PL-21 NEf5ZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfOPZZsOyEQvF2= M{jiTVczKGh? NHX1SVVFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M1z5c|IzPDh6MkS5
KG-1 M3;3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWzJO69VQ>? MYe3NkBp NGX6bVVFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 Mm\SNlI1QDh{NEm=
A172 NYjLcmdXS3m2b4TvfIlkKEG|c3H5 MlrrNVAxKM7:TR?= NWL6b3dNOjRiaB?= NIeyW3hFVVOR NEDpfoJKSzVyPUCuNVIxKM7:TR?= NFPqOlIzOjJ5NEO5PS=>
U87 MWfDfZRwfG:6aXOgRZN{[Xl? MmjrNVAxKM7:TR?= MkLiNlQhcA>? MoS1SG1UVw>? NWTFV2I5UUN3ME2wMlExPSEQvF2= MWSyNlI4PDN7OR?=
U251 M{niVWN6fG:2b4jpZ{BCe3OjeR?= NVTrSlJyOTByIN88US=> NVrn[Fg5OjRiaB?= Mk\4SG1UVw>? M3nQXmlEPTB;MD6xNFAh|ryP MlfiNlIzPzR|OUm=
T98 MXnDfZRwfG:6aXOgRZN{[Xl? MVmxNFAh|ryP NX;1Z25bOjRiaB?= M4jO[GROW09? NXriR5ROUUN3ME2wMlEzPSEQvF2= NXHSZWtUOjJ{N{SzPVk>
LN18 MVjDfZRwfG:6aXOgRZN{[Xl? MlXrNVAxKM7:TR?= M3TTZVI1KGh? Moj3SG1UVw>? Ml3OTWM2OD1yLkKxNEDPxE1? M1z5PFIzOjd2M{m5
LN443 M4C3dmN6fG:2b4jpZ{BCe3OjeR?= MYSxNFAh|ryP NEXLZYszPCCq NEnod2hFVVOR Mmm3TWM2OD1yLkKyNEDPxE1? NUXCO5RUOjJ{N{SzPVk>
HF66 MXHDfZRwfG:6aXOgRZN{[Xl? NFvqT2gyODBizszN Ml7sNlQhcA>? M4Ll[mROW09? MnvFTWM2OD1yLkKyOUDPxE1? NFvNWXEzOjJ5NEO5PS=>
HF2303 NHXLOJpEgXSxdH;4bYMhSXO|YYm= NX;JN3ZCOTByIN88US=> MUeyOEBp MmrvSG1UVw>? NHTqdnNKSzVyPUCuNFYxKM7:TR?= NX7rTphKOjJ{N{SzPVk>
HF2359 M4Pw[2N6fG:2b4jpZ{BCe3OjeR?= NVXST5ZwOTByIN88US=> NGGwU2EzPCCq MonSSG1UVw>? NH7QdJJKSzVyPUCuNFYxKM7:TR?= MljYNlIzPzR|OUm=
HF2414 M1i4UmN6fG:2b4jpZ{BCe3OjeR?= NEjZWmUyODBizszN MknKNlQhcA>? NIK4SpdFVVOR NV\oXFJ{UUN3ME2wMlA5OCEQvF2= NVizUnBEOjJ{N{SzPVk>
A-673 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P4[VExKM7:TR?= NXK2UlR{QTZiaB?= NGHwbYZFVVOR Mme2TWM2OD1yLkCzNkDPxE1? MY[yNVQ1QDV7MR?=
TC-32 NEDCTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNEDPxE1? MoO0PVYhcA>? NGDMSJVFVVOR NG\TVYFKSzVyPUCuNFM6KM7:TR?= M4rzfVIyPDR6NUmx
TC-71 NF\VdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn6OVFXOTBizszN NETs[Jc6PiCq NV3iW45WTE2VTx?= M3\L[WlEPTB;MD6xNFIh|ryP Mn;VNlE1PDh3OUG=
SK-N-MC M16zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\lNVAh|ryP MV65OkBp M2PjT2ROW09? MlW5TWM2OD1yLkC3NkDPxE1? NHfkRXQzOTR2OEW5NS=>
CHLA-9 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxNEDPxE1? NXq4d4U4QTZiaB?= M1XCVGROW09? MX;JR|UxRTBwMEG4JO69VQ>? MnTwNlE1PDh3OUG=
CHLA-10 NXPldoZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vrflExKM7:TR?= M2W1NFk3KGh? NH\UZ4JFVVOR M4Xob2lEPTB;MD6wOlAh|ryP NXrReXNpOjF2NEi1PVE>
CHLA-25 M{LDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfqd4MyOCEQvF2= MXe5OkBp M1fERmROW09? NV7o[FBKUUN3ME2wMlE3QCEQvF2= MWWyNVQ1QDV7MR?=
CHLA-32 NE\MSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFblcyOCEQvF2= NET4cGw6PiCq MX\EUXNQ NF7KWoNKSzVyPUCuNVM3KM7:TR?= NWrScnlsOjF2NEi1PVE>
CHLA-56 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHOFExKM7:TR?= MXi5OkBp M2DPV2ROW09? MmnSTWM2OD1zMDFOwG0> MVKyNVQ1QDV7MR?=
CHLA-258 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXlPIoyOCEQvF2= MXK5OkBp MYnEUXNQ M4PtZWlEPTB;MD6xN|Ih|ryP M4n0NVIyPDR6NUmx
COG-E-352 NGrpbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPiVVR[OTBizszN M2Tud|k3KGh? MkjtSG1UVw>? NYjwd3pZUUN3ME2wMlA1OyEQvF2= NXjEc|QzOjF2NEi1PVE>
CHLA-90 NX\DVms1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ENFIyOCEQvF2= NYnFc5FlQTZiaB?= NVj0[YZqTE2VTx?= NHvXWYVKSzVyPUCuNFYyKM7:TR?= MkTINlE1PDh3OUG=
CHLA-119 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3rNVAh|ryP NGjZZYc6PiCq NYDpfoZYTE2VTx?= MUfJR|UxRTBwMEKyJO69VQ>? NIrHcGYzOTR2OEW5NS=>
CHLA-122 NFvJSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HY[FExKM7:TR?= MVe5OkBp MUfEUXNQ MnvXTWM2OD1yLkCxPUDPxE1? MnLiNlE1PDh3OUG=
CHLA-136 NID5R3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNEDPxE1? M1PrPFk3KGh? NVfoR2YxTE2VTx?= MWrJR|UxRTBwMEO5JO69VQ>? NGi5OXgzOTR2OEW5NS=>
CHLA-140 M1f4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPsXmoyOCEQvF2= Mmn1PVYhcA>? NETvTmdFVVOR NV61[HRjUUN3ME2wMlAzPiEQvF2= NYTYS|hqOjF2NEi1PVE>
LA-N-6 NH:wRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7hV|hGOTBizszN NFfZ[4Y6PiCq NHvvZWdFVVOR M2TZUWlEPTB;MD6wOVQh|ryP NIjnXYozOTR2OEW5NS=>
NB-1643 NUD2UGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDsNVAh|ryP MVW5OkBp MUHEUXNQ Mof0TWM2OD1yLkCzO{DPxE1? NYHORXF5OjF2NEi1PVE>
NB-EBc1 NHXmfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvsXmlMOTBizszN Mn21PVYhcA>? NWDqWWR5TE2VTx?= MXXJR|UxRTBwMEWwJO69VQ>? MljSNlE1PDh3OUG=
SK-N-BE-1 NX;hcHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzC[2oyOCEQvF2= NEXV[nc6PiCq MY\EUXNQ M4TCXmlEPTB;MD6wNlgh|ryP MlXQNlE1PDh3OUG=
SK-N-BE-2 M3nNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XpZlExKM7:TR?= NWDZOpZuQTZiaB?= MmTZSG1UVw>? NXezbVVpUUN3ME2wMlA{PiEQvF2= NYPaelBkOjF2NEi1PVE>
SMS-KAN M4XjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTLOYoyOCEQvF2= NV7N[3FTQTZiaB?= MmfSSG1UVw>? NWTrSndPUUN3ME2wMlA{PCEQvF2= MXqyNVQ1QDV7MR?=
SMS-KANR M1i2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\1e|dIOTBizszN NIrEW5E6PiCq M4jKZWROW09? NX;XXlFYUUN3ME2wMlAzPiEQvF2= NX;HbZRkOjF2NEi1PVE>
SMS-KCN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSxNEDPxE1? M4nTelk3KGh? NVvLUHFkTE2VTx?= M1Ple2lEPTB;MD6wNVkh|ryP NILld3QzOTR2OEW5NS=>
SMS-KCNR NWTybYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSxNVAh|ryP NVTUfWg2QTZiaB?= NVH5Zm5jTE2VTx?= MXTJR|UxRTBwMEGwJO69VQ>? NE\WXHkzOTR2OEW5NS=>
SMS-LHN MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPYNI0yOCEQvF2= M2K1blk3KGh? M1riVGROW09? NEO1SHNKSzVyPUCuNFMzKM7:TR?= MV[yNVQ1QDV7MR?=
SMS-MSN MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIThWY4yOCEQvF2= NHrYd5o6PiCq MUDEUXNQ MVrJR|UxRTBwMEKyJO69VQ>? NHXiVWMzOTR2OEW5NS=>
SMS-SAN NXTaUo9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL3NVAh|ryP M1npdVk3KGh? MWfEUXNQ M3vITWlEPTB;MD6wNlAh|ryP Mn33NlE1PDh3OUG=
Granta-4 M3m1c2N6fG:2b4jpZ{BCe3OjeR?= NWnQbHNxOTBizszN MmXZO{Bl Mo[1TWM2OD1yLkC0NEDPxE1? NWfzVHp5OjF{OUG4Olc>
DB NUXNS3gzS3m2b4TvfIlkKEG|c3H5 Mn30NVAh|ryP MUO3JIQ> NVPWemtOUUN3ME2wMlA1OiEQvF2= MXmyNVI6OTh4Nx?=
RL NWnCPY53S3m2b4TvfIlkKEG|c3H5 MnOwNVAh|ryP MXO3JIQ> M1fQNGlEPTB;MD6wNVUh|ryP MV:yNVI6OTh4Nx?=
K562 NGPGcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmxNEDPxE1? MV[5OkBp MUfJR|UxRTBwMEi3JO69VQ>? M1nwUVIyODlzNkOz
LAMA-84 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNEDPxE1? MknwPVYhcA>? MVnJR|UxRTBwMEW3JO69VQ>? NWGwb5BWOjFyOUG2N|M>
MM15 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyyOEDPxE1? NX\jRnpTPzJiaB?= M2XUNmROW09? M1zlb2lEPTB;MD6xN{DPxE1? M3HPflIxOzh{OES0
OPM1 NVnJRXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm0JO69VQ>? NGjJNmY4OiCq MkixSG1UVw>? NVfneJhYUUN3ME2wMlA{KM7:TR?= MnrRNlA{QDJ6NES=
RPM1 NH74N45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjTPVBGPCEQvF2= NEDQ[Iw4OiCq NWDxPJo5TE2VTx?= NVPhfWJzUUN3ME2xNE4{OiEQvF2= Mn[5NlA{QDJ6NES=
INA6 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\KOEDPxE1? MUe3NkBp NFPuOJRFVVOR NHLP[XBKSzVyPUCuNFAzKM7:TR?= MVuyNFM5Ojh2NB?=
OPM2 NIKzZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3XNFU5PCEQvF2= NF21VIk4OiCq M2DnOWROW09? NVuySWFLUUN3ME20MlM4KM7:TR?= NFXHRYMzODN6Mki0OC=>
MM1R NHHTS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jWOFQh|ryP NXrpVG9DPzJiaB?= MYjEUXNQ NGHad3NKSzVyPUGuOlgh|ryP MVmyNFM5Ojh2NB?=
DOX40 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\xSVl3PCEQvF2= Mo\lO|IhcA>? MlfiSG1UVw>? NH7X[mdKSzVyPUWuOFgh|ryP MnqwNlA{QDJ6NES=
LR5 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD3OEDPxE1? NGTKSpU4OiCq NH;RbHZFVVOR NXfVdJN1UUN3ME2yMlU{KM7:TR?= M2e4flIxOzh{OES0
U266 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjqfldqPCEQvF2= NHLQ[I84OiCq MUXEUXNQ MkfqTWM2OD1zLkSzJO69VQ>? NYHnbZZTOjB|OEK4OFQ>
RD MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTPNVAh|ryP NGe2Upo6PiCq MWDJR|UxRTBwMkK4JO69VQ>? M3TKeFIxOTB6M{O4
Rh41 NHzNbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXWNVAh|ryP Mlr1PVYhcA>? NEDiUVlKSzVyPUCuNFkxKM7:TR?= M2eyNlIxOTB6M{O4
Rh30 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPRNVAh|ryP MnK4PVYhcA>? NEj4bJdKSzVyPUCuNlMxKM7:TR?= MYKyNFExQDN|OB?=
BT-12 NVz1UVZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HPeFExKM7:TR?= MmPKPVYhcA>? NX7pTnhIUUN3ME2wMlA3OCEQvF2= M4C4ZVIxOTB6M{O4
CHLA-266 NEnYTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jaOlExKM7:TR?= MXK5OkBp M33WSGlEPTB;MD6wO|Ih|ryP MXWyNFExQDN|OB?=
TC-71 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jpXlExKM7:TR?= M{HSN|k3KGh? NF[xPJZKSzVyPUCuNVAzKM7:TR?= NHHyTYUzODFyOEOzPC=>
SJ-GBM2 NYe4dXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;5W|ExKM7:TR?= NXLQSGxyQTZiaB?= NYLSSFFEUUN3ME2wMlA2OCEQvF2= NFfrO4IzODFyOEOzPC=>
NALM-6 NVe4UYY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XqcFExKM7:TR?= MUW5OkBp MYTJR|UxRTBwME[yJO69VQ>? NFv1WZAzODFyOEOzPC=>
COG-LL-317 NGG1UHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexNEDPxE1? MkLXPVYhcA>? NX;MSplKUUN3ME2wMlA1PyEQvF2= MVKyNFExQDN|OB?=
RS4-11 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjab5dlOTBizszN MV:5OkBp Mne2TWM2OD1yLkCxPEDPxE1? MXeyNFExQDN|OB?=
MOLT-4 NEm4XY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TtU|ExKM7:TR?= MnvoPVYhcA>? NUnYd5FuUUN3ME2wMlAzPiEQvF2= NHSyWZAzODFyOEOzPC=>
CCRF-CEM NGGxNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLZNVAh|ryP M1;xO|k3KGh? M1PIc2lEPTB;MD6wPVQh|ryP M1\DV|IxOTB6M{O4
Kasumi-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDMNVAh|ryP NUXLTZI5QTZiaB?= NHfCPVVKSzVyPUCuNVA{KM7:TR?= M1\qNFIxOTB6M{O4
Karpas-299 M4DFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HxXFExKM7:TR?= MYG5OkBp MmjiTWM2OD1yLkCzPEDPxE1? Mn\mNlAyODh|M{i=
Ramos-RA1 NFTmT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TZTlExKM7:TR?= MUi5OkBp M2G2NGlEPTB;MD6xNlch|ryP M4SzXFIxOTB6M{O4

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID